tetano
Editor, Senior Moderator
Vaccine X
. 2023 Aug 4;15:100365.
doi: 10.1016/j.jvacx.2023.100365. eCollection 2023 Dec. Estimated health and economic impact of using high-dose influenza vaccine on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia
C Raina MacIntyre[SUP] 1 [/SUP], J Kevin Yin[SUP] 2 3 [/SUP], Christian Felter[SUP] 4 [/SUP], Robert I Menzies[SUP] 5 [/SUP], Edward Thommes[SUP] 6 7 [/SUP], Nathalie Largeron[SUP] 8 [/SUP], Aye M Moa[SUP] 1 [/SUP], Mallory Trent[SUP] 1 [/SUP], Valentina Costantino[SUP] 1 [/SUP], Seulki Choi[SUP] 9 [/SUP], Fabián P Alvarez[SUP] 8 [/SUP]
Affiliations
Background: Standard dose influenza vaccine provides moderate protection from infection, but with lower effectiveness among the elderly. High dose and adjuvanted vaccines (HD-TIV and aTIV) were developed to address this. This study aims to estimate the incremental health and economic impact of using HD-TIV (high dose trivalent vaccine) instead of aTIV (adjuvanted trivalent vaccine) on respiratory and circulatory plus respiratory hospitalizations of older people (≥65 years) in Australia.
Methods: This is a modelling study comparing predicted hospitalization outcomes in people receiving HD-TIV or aTIV during an average influenza season in Australia. Hospitalization records of Australian adults ≥65 years of age from 01 April to 30 November during 15 influenza seasons (2002-2017 excluding 2009, which was a pandemic) were extracted from the Australian Institute of Health and Welfare [AIHW] and used to calculate hospitalisation rates during an average season. Relative vaccine effectiveness data for aTIV and HD-TIV were used to estimate morbidity burden related to influenza.
Results: Between 2002 and 2017, the average respiratory hospitalization rate among older people during influenza season (April-November) was 3,445/100,000 population-seasons, with an average cost of AU$ 7,175 per admission. The average circulatory plus respiratory hospitalization rate among older Australian people during that time was 10,393/100,000 population-seasons, with an average cost of AU$ 7829 per admission. For older Australians, HD-TIV may avert an additional 6,315-9,410 respiratory admissions each year, with an incremental healthcare cost saving of AU$ 15.9-38.2 million per year compared to aTIV. Similar results were also noted for circulatory plus respiratory hospitalizations.
Conclusions: From the modelled estimations, HD-TIV was associated with less economic burden and fewer respiratory, and circulatory plus respiratory hospitalizations than aTIV for older Australians.
Keywords: Cardiovascular disease; Older adults; Seasonal influenza; Trivalent inactivated high-dose influenza vaccine (HD-TIV); Vaccine effectiveness.
. 2023 Aug 4;15:100365.
doi: 10.1016/j.jvacx.2023.100365. eCollection 2023 Dec. Estimated health and economic impact of using high-dose influenza vaccine on respiratory and circulatory plus respiratory hospitalizations of older adults in Australia
C Raina MacIntyre[SUP] 1 [/SUP], J Kevin Yin[SUP] 2 3 [/SUP], Christian Felter[SUP] 4 [/SUP], Robert I Menzies[SUP] 5 [/SUP], Edward Thommes[SUP] 6 7 [/SUP], Nathalie Largeron[SUP] 8 [/SUP], Aye M Moa[SUP] 1 [/SUP], Mallory Trent[SUP] 1 [/SUP], Valentina Costantino[SUP] 1 [/SUP], Seulki Choi[SUP] 9 [/SUP], Fabián P Alvarez[SUP] 8 [/SUP]
Affiliations
- PMID: 37609557
- PMCID: PMC10440578
- DOI: 10.1016/j.jvacx.2023.100365
Background: Standard dose influenza vaccine provides moderate protection from infection, but with lower effectiveness among the elderly. High dose and adjuvanted vaccines (HD-TIV and aTIV) were developed to address this. This study aims to estimate the incremental health and economic impact of using HD-TIV (high dose trivalent vaccine) instead of aTIV (adjuvanted trivalent vaccine) on respiratory and circulatory plus respiratory hospitalizations of older people (≥65 years) in Australia.
Methods: This is a modelling study comparing predicted hospitalization outcomes in people receiving HD-TIV or aTIV during an average influenza season in Australia. Hospitalization records of Australian adults ≥65 years of age from 01 April to 30 November during 15 influenza seasons (2002-2017 excluding 2009, which was a pandemic) were extracted from the Australian Institute of Health and Welfare [AIHW] and used to calculate hospitalisation rates during an average season. Relative vaccine effectiveness data for aTIV and HD-TIV were used to estimate morbidity burden related to influenza.
Results: Between 2002 and 2017, the average respiratory hospitalization rate among older people during influenza season (April-November) was 3,445/100,000 population-seasons, with an average cost of AU$ 7,175 per admission. The average circulatory plus respiratory hospitalization rate among older Australian people during that time was 10,393/100,000 population-seasons, with an average cost of AU$ 7829 per admission. For older Australians, HD-TIV may avert an additional 6,315-9,410 respiratory admissions each year, with an incremental healthcare cost saving of AU$ 15.9-38.2 million per year compared to aTIV. Similar results were also noted for circulatory plus respiratory hospitalizations.
Conclusions: From the modelled estimations, HD-TIV was associated with less economic burden and fewer respiratory, and circulatory plus respiratory hospitalizations than aTIV for older Australians.
Keywords: Cardiovascular disease; Older adults; Seasonal influenza; Trivalent inactivated high-dose influenza vaccine (HD-TIV); Vaccine effectiveness.